Incidence rates of exocrine and endocrine pancreatic cancers in the United States

Zhou, Jing; Enewold, Lindsey; Stojadinovic, Alexander; Clifton, Guy T.; Potter, John F.; Peoples, George E.; Zhu, Kangmin

doi:10.1007/s10552-010-9512-y

Cited by 61 publications

(41 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Insulinoma is the most common functional pancreatic neuroendocrine tumor, with an incidence of 0.1-0.3 cases per 100,000 persons per year 1 . In over 90% of cases, they are solitary and benign.…”

Section: Introductionmentioning

confidence: 99%

“…3,4 Insulinoma may be associated with a hereditary syndrome in nearly 10% of patients, the most common being multiple endocrine neoplasia type 1 (MEN1) 5 . Insulinomas are evenly distributed throughout the pancreas and are usually less than 2 cm in size in approximately 90% of cases 1 . This makes them challenging to localize by traditional imaging techniques such as transabdominal ultrasound (US), contrast enhanced CT, and MRI.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Localization of Insulinoma Using 68Ga-DOTATATE PET/CT Scan

Nockel

Babic

Millo

et al. 2016

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

Context. The reliable localization of insulinoma is critical for the successful surgical treatment.Objective. This study compared the accuracy of 68 Gallium (Ga)-DOTATATE PET/CT to anatomic imaging modalities, selective arterial secretagogue injection (SASI), and intraoperative ultrasound (IOUS) and palpation for localizing insulinoma in patients who were biochemically cured. Design, Setting, and Patients. We conducted a retrospective analysis of 31 patients who had an insulinoma confirmed on histology and were biochemically cured. The results of CT, MRI, transabdominal US, IOUS, 68 Ga-DOTATATE PET/CT, SASI, and operative findings were analyzed. Intervention, Main Outcome Measures, Results: The insulinomas were correctly localized in 17 out of 31 (55%) of patients by CT, in 17 out of 28 (61%) by MRI, in 6 out of 28 (21%) by US, and in 9 out of 10 (90%) by 68 Ga-DOTATATE. IOUS was performed in 31 patients, and 29 of them had an insulinoma successfully localized (93.5%). Thirty patients underwent SASI, and the insulinoma was regionalized in 28 out of 30 patients (93%). In 19 out of 23 patients (83%), manual palpation identified insulinoma. In patients who had all four noninvasive imaging studies, CT was concordant with 68 Ga-DOTATATE in 6 out of 9 patients (67%); MRI in 8 out of 9 (78%); US in 0 out of 9; and in 1 out of 9 patients (11%) the lesion was only seen by 68 Ga-DOTATATE. Conclusions:68 Ga-DOTATATE PET/CT identifies most insulinomas and may be considered as an adjunct imaging study when all imaging studies are negative and when a minimally invasive surgical approach is planned.PRECIS: We studied 68Ga-DOTATATE PET/CT imaging in patients with insulinoma and found it identifies most tumors and should be considered as an adjunct imaging study.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Localization of Insulinoma Using 68Ga-DOTATATE PET/CT Scan

Nockel

Babic

Millo

et al. 2016

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

show abstract

“…Pancreatic neuroendocrine tumors (pancreatic NET) are increasing in incidence [1,2] and, with improved diagnostics and better recognition within the medical community, their prevalence is higher than previously thought [3]. The natural course of the disease varies according to the type of primary tumor, tumor size, and histological grade.…”

Section: Introductionmentioning

confidence: 99%

From Targets to Treatments: A Review of Molecular Targets in Pancreatic Neuroendocrine Tumors

2011

View full text Add to dashboard Cite

Pancreatic neuroendocrine tumors (pancreatic NET) are relatively rare, slowly growing tumors, although their incidence is increasing, and patients may survive for several years with metastatic disease. Apart from symptomatic relief, there have been few treatment options for these tumors in the past. More recently, investigators have explored the potential of molecularly targeted agents in treating pancreatic NET, with some success. In this review, we consider the data supporting exploitation of different targets in pancreatic NET, including peptide receptors, receptor tyrosine kinases (involved in tumor angiogenesis and more directly supporting tumor growth), and intracellular targets, such as the mammalian target of rapamycin (mTOR), which has a central role in regulating cell growth, metabolism, and apoptosis. Probably due to the paucity of pancreatic NET, many clinical trials to date have included heterogeneous NET populations, and there are few randomized studies of this specific patient population. Very recently, promising results have been achieved in placebo-controlled, phase III trials with the multitargeted tyrosine kinase inhibitor, sunitinib, and the mTOR inhibitor, everolimus. These agents have been approved or are currently being reviewed by authorities for use in patients with pancreatic NET. Here we review potential molecular targets in pancreatic NET and summarize the available data for targeted agents from phase II and III trials open to patients with this tumor.

show abstract

“…Pancreatic neuroendocrine tumors (pNETs) are uncommon neoplasms with an incidence of 1 -10 per 1 million in the general population (1,2). pNETs can occur sporadically or as part of the hereditary multiple tumor syndromes von Hippel-Lindau (VHL) disease and multiple endocrine neoplasia type 1 (MEN1).…”

Section: Introductionmentioning

confidence: 99%